One-time gene therapy for severe sickle cell and transfusion anemia
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a single dose of gene therapy (CTX001) to improve outcomes for people with severe sickle cell disease or transfusion-dependent beta-thalassemia. It aims to see how well it works and whether it is safe, especially after a planned stem cell transplant process.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have either transfusion-dependent beta-thalassemia or severe sickle cell disease
- You have a history of needing frequent red blood transfusions (for beta-thalassemia)
- For sickle cell disease, you’ve had frequent severe pain crises (VOC) in the past two years
- Your medical team believes you’re eligible for an autologous stem cell transplant (using your own stem cells)
- You do not have a fully matched sibling or relative donor available (as decided by your team)
- You have not had a prior stem cell transplant, and you don’t have a serious active infection or certain specific genetic/injury conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This gene therapy trial uses a modified virus to deliver a healthy gene into your own stem cells. The goal is to help your body make normal red blood cells so you may need fewer or no transfusions.
This trial tests a one-time gene therapy using your own blood stem cells to treat severe beta-thalassemia. It may help you stop needing regular blood transfusions.
This trial tests a one-time treatment that uses your own (autologous) stem cells that have been changed by gene methods, then returned to you to help manage transfusion-dependent beta-thalassemia. It aims to check safety and whether it can reduce the need for frequent blood transfusions or improve blood health.
This trial tests a new gene therapy called KL003 for people with severe sickle cell disease. The goal is to see if it can reduce painful episodes and improve quality of life.
This trial tests a new gene therapy that edits your own blood stem cells to help them make more fetal hemoglobin, which can prevent sickling and reduce the need for transfusions. It is for people with severe sickle cell disease or beta thalassemia who do not have a matched sibling donor.
This study tests an experimental gene therapy called YOLT-204 for people with sickle cell disease or thalassemia. It aims to see if the treatment is safe and can help reduce symptoms, and participants will be followed long-term.
Hear when a new Beta-Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.